Short answer
aTYR PHARMA INC (ATYR) filed an 8-K current report with the SEC on July 31, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item EX-99.1 (Exhibit EX-99.1). Kyorin collaboration terminated July 30, 2026, ahead of the previously expected 90-day termination timeline.
aTYR PHARMA INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.02 · Termination of a Material Definitive Agreement
- Kyorin collaboration terminated July 30, 2026, ahead of the previously expected 90-day termination timeline
- Efzofitimod development and commercialization rights in Japan reverted to aTyr
- aTyr now holds global rights for efzofitimod across all forms of interstitial lung disease
- Ancillary agreements terminated, with wind-down activities governed by the termination agreement
Item EX-99.1 · Exhibit EX-99.1
- Kyorin collaboration terminated July 30, 2026, ending the 2020 license partnership and dissolving the joint steering committee
- aTyr regains perpetual, royalty-free worldwide rights to efzofitimod, including exclusive rights to New Kyorin IP and New Joint IP
- Kyorin must transfer clinical, regulatory, pharmacology, and manufacturing records, enabling aTyr to resume development and commercialization
- Kyorin will support Japan transition activities, including orphan-drug designation transfer and clinical-document archiving
- Mutual release eliminates pre-termination claims, while each party bears its own expenses and no outstanding development-cost payments remainેણ
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other aTYR PHARMA INC 8-K filings
Get the next ATYR 8-K as it lands
Follow ATYR for push alerts, or ask the research agent what this filing means.